Trial Profile
A Phase 3, Multicenter, 22-Week, Double-Blind and 30-Week Open-Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Lumbar Spine
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase III
Latest Information Update: 13 Jun 2023
Price :
$35
*
At a glance
- Drugs Ibuprofen (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Sponsors Techfields Pharma
- 08 Jun 2023 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 07 Oct 2022 Planned End Date changed from 14 Jul 2024 to 30 Jul 2025.
- 07 Oct 2022 Planned primary completion date changed from 14 Jul 2024 to 30 Jul 2024.